Smiths Medical is committed to safety. When it comes to regional anesthesia solutions, the Portex® epidural portfolio
has delivered on that commitment for more than 40 years. Designed with
safety in mind from the tiniest details and the most miniscule
movements, from pump to patient.
UNITE DES SOINS PALLIATIFS
Zahle et Bekaa. LIBAN
PALLIATIVE CARE UNIT
Zahle and Bekaa. LEBANON
Translate
Wednesday, August 27, 2014
New guidelines drafted by the American Pain Society
(APS) for the safe administration of methadone for the first time focus
particular attention on the potential for abuse and misuse of the drug,
highlighting the need for additional awareness and education within the
pain management community, after a significant increase in deaths
related to its use.
ISSUE: AUGUST 2014 | VOLUME: 12(8)
New guidelines drafted by the American Pain Society
(APS) for the safe administration of methadone for the first time focus
particular attention on the potential for abuse and misuse of the drug,
highlighting the need for additional awareness and education within the
pain management community, after a significant increase in deaths
related to its use.
The new guidelines, which were published in the April issue of The Journal of Pain (2014;15:338-365), address several key areas, including patient assessment, patient education/counseling and treatment monitoring; in some cases, they also propose the use of alternative medications. Among other recommendations, the new guidelines call for stratification of patients based on their risk for substance abuse prior to methadone treatment, and suggest that the drug be administered at a low starting dose (30-40 mg daily; slow titration as needed) to reduce the incidence of unintended drug accumulation and accidental overdose.
The guidelines also address the cardiovascular risks associated with the drug. A statement released by the APS in conjunction with the new guidelines describes earlier methadone protocols as focusing primarily on these risks, while ignoring the potential for abuse and misuse. According to Roger Chou, MD, head of the APS Clinical Practice Guideline Program and associate professor of medicine at Oregon Health & Sciences, University in Portland, “alarming data” on methadone-related deaths prompted the society to change the focus. He cited Centers for Disease Control and Prevention (CDC) statistics that show an increase in deaths associated with methadone, from less than 1,000 in 1999 to nearly 5,000 in 2008. He added that although methadone accounts for “about 10% or less” of all opioids prescribed, the CDC has linked the drug with roughly one-third of all prescription opioid-related deaths.
“These trends occurred in the context of markedly increased prescribing of opioids in general for chronic pain, and increased use of methadone as a less expensive alternative to other long-acting opioids,” he said.
In addition to addressing its use in the management of pain, the new guidelines focus on methadone as a treatment for patients with opioid addiction. In this context, the authors recommend that routine patient monitoring include echocardiograms and urine drug testing. They also propose buprenorphine as an alternative for these patients.
Although the guidelines were written for use by all clinicians who prescribe methadone, Dr. Chou, who served as lead author, admitted that many of the recommendations were aimed at primary care physicians. “A lot of prescribing for chronic pain occurs in primary care settings, where some clinicians may perceive methadone to be interchangeable with other opioids, when that clearly isn’t the case due to its long half-life and potential for QTc prolongation,” he told Pain Medicine News. “It is important for clinicians to understand the unique properties of methadone that can increase risk, the steps that can be taken to reduce risks, and consider alternative opioids and other treatments before prescribing methadone.”
Family practitioner Louis Kurzitzky, MD, said that the “limitations of methadone are well recognized” at his clinic, but he acknowledged that some of his colleagues may not be aware of proper monitoring protocols for patients receiving the drug for the treatment of pain. His only concern is that not all primary care physicians read The Journal of Pain, and he recommended that the authors seek to publish the guidelines in other journals, with wider readership across specialties and disciplines.
“The guidelines are a critical step forward, [as they] put clinicians on notice that methadone deserves its own special categorization because of differences in administration and monitoring [compared with] other opioids,” said Dr. Kuritzky, who is also clinical assistant professor at the University of Florida in Gainesville. He was not involved in the development of the new guidelines.
—Bria
The new guidelines, which were published in the April issue of The Journal of Pain (2014;15:338-365), address several key areas, including patient assessment, patient education/counseling and treatment monitoring; in some cases, they also propose the use of alternative medications. Among other recommendations, the new guidelines call for stratification of patients based on their risk for substance abuse prior to methadone treatment, and suggest that the drug be administered at a low starting dose (30-40 mg daily; slow titration as needed) to reduce the incidence of unintended drug accumulation and accidental overdose.
The guidelines also address the cardiovascular risks associated with the drug. A statement released by the APS in conjunction with the new guidelines describes earlier methadone protocols as focusing primarily on these risks, while ignoring the potential for abuse and misuse. According to Roger Chou, MD, head of the APS Clinical Practice Guideline Program and associate professor of medicine at Oregon Health & Sciences, University in Portland, “alarming data” on methadone-related deaths prompted the society to change the focus. He cited Centers for Disease Control and Prevention (CDC) statistics that show an increase in deaths associated with methadone, from less than 1,000 in 1999 to nearly 5,000 in 2008. He added that although methadone accounts for “about 10% or less” of all opioids prescribed, the CDC has linked the drug with roughly one-third of all prescription opioid-related deaths.
“These trends occurred in the context of markedly increased prescribing of opioids in general for chronic pain, and increased use of methadone as a less expensive alternative to other long-acting opioids,” he said.
In addition to addressing its use in the management of pain, the new guidelines focus on methadone as a treatment for patients with opioid addiction. In this context, the authors recommend that routine patient monitoring include echocardiograms and urine drug testing. They also propose buprenorphine as an alternative for these patients.
Although the guidelines were written for use by all clinicians who prescribe methadone, Dr. Chou, who served as lead author, admitted that many of the recommendations were aimed at primary care physicians. “A lot of prescribing for chronic pain occurs in primary care settings, where some clinicians may perceive methadone to be interchangeable with other opioids, when that clearly isn’t the case due to its long half-life and potential for QTc prolongation,” he told Pain Medicine News. “It is important for clinicians to understand the unique properties of methadone that can increase risk, the steps that can be taken to reduce risks, and consider alternative opioids and other treatments before prescribing methadone.”
Family practitioner Louis Kurzitzky, MD, said that the “limitations of methadone are well recognized” at his clinic, but he acknowledged that some of his colleagues may not be aware of proper monitoring protocols for patients receiving the drug for the treatment of pain. His only concern is that not all primary care physicians read The Journal of Pain, and he recommended that the authors seek to publish the guidelines in other journals, with wider readership across specialties and disciplines.
“The guidelines are a critical step forward, [as they] put clinicians on notice that methadone deserves its own special categorization because of differences in administration and monitoring [compared with] other opioids,” said Dr. Kuritzky, who is also clinical assistant professor at the University of Florida in Gainesville. He was not involved in the development of the new guidelines.
Pain Patients Can Have Good Outcomes With Long-Term Opioids
Long-term
opioid treatment can produce positive outcomes in chronic noncancer
pain when physicians prescribe it carefully to individuals who have low
risks for addiction and overdose, according to the results of a
systematic review.
Andrea Furlan, MD, PhD, and her colleagues searched Medline, EMBASE, CINAHI, PsycINFO, Central and Business Source Premier for studies published since 2000 on function and quality of life (QOL) in patients taking long-term opioids for chronic noncancer pain.
The studies included in the analysis involved chronic noncancer pain that lasted longer than three months, opioid use for longer than three months, and outcomes that included measures of function and QOL. Most of the studies excluded patients who had comorbidities and psychiatric diagnoses. The majority of the patients were monitored closely by health care professionals, and were on doses of opioids that were less than approximately 200 mg per day.
The initial literature search by Dr. Furlan, a scientist at the Institute for Work & Health, and pain physician at University Health Network, Toronto, Canada, and her colleagues yielded 16,288 references. The studies focused on function and QOL, as well as outcomes of misuse, abuse, addiction, and falls and fractures. They then excluded all papers that lacked sufficient detail for a careful analysis.
Ultimately, the researchers performed a meta-analysis of pre–post results on eight randomized controlled trials, eight open-label extension studies from randomized controlled trials and nine observational controlled studies. These 25 studies included 4,719 patients, 3,160 of whom (67%) completed the studies. The analysis focused on these latter patients.
The investigators found that long-term opioid use resulted in significantly improved function, and physical and mental QOL.
Mark Sullivan, MD, PhD, professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, said that although Dr. Furlan and her collaborators do “careful work,” he had queries about the study, which was presented at the Canadian Pain Society’s 2014 annual meeting (poster 56).
“First, in pre–post studies without a control group, estimates of efficacy are strongly related to who drops out. Since almost all patients who drop out are not doing well on the drug, the mean pre–post differences can grossly overstate efficacy. We are told 67% were completers. How did this 67% compare with those who did drop out?” Dr. Sullivan noted in an email to Pain Medicine News. He also pointed out that the populations in the studies included in the systematic review were not typical.
Dr. Furlan said she and her team discussed at great length these points, and other potential critiques, while they were completing the systematic review.
She said that, for publication, the paper will include an uncertainty analysis that takes into account the worst-case scenario of a high dropout rate and the resulting underestimates of complications and overestimates of opioid effectiveness. Dr. Furlan also conceded that the patients in the systematic review represented a minority of typical chronic pain patients, because they did not have risk factors and were monitored carefully.
“It is true that most of these conditions are not followed in real-life opioid prescribing. [In clinical practice] I see a lot of careless prescribing, which can be characterized as ‘high-risk patients’ and/or ‘high-risk prescriptions.’ When you mix both, it is dangerous,” Dr. Furlan said in an interview with Pain Medicine News. “But when physicians and their teams take the time to carefully screen patients, keep them on as low a dose as possible and monitor them very regularly, our results show that the outcomes can be very satisfactory.”
—Rosemary Frei, MSc
Andrea Furlan, MD, PhD, and her colleagues searched Medline, EMBASE, CINAHI, PsycINFO, Central and Business Source Premier for studies published since 2000 on function and quality of life (QOL) in patients taking long-term opioids for chronic noncancer pain.
The studies included in the analysis involved chronic noncancer pain that lasted longer than three months, opioid use for longer than three months, and outcomes that included measures of function and QOL. Most of the studies excluded patients who had comorbidities and psychiatric diagnoses. The majority of the patients were monitored closely by health care professionals, and were on doses of opioids that were less than approximately 200 mg per day.
The initial literature search by Dr. Furlan, a scientist at the Institute for Work & Health, and pain physician at University Health Network, Toronto, Canada, and her colleagues yielded 16,288 references. The studies focused on function and QOL, as well as outcomes of misuse, abuse, addiction, and falls and fractures. They then excluded all papers that lacked sufficient detail for a careful analysis.
Ultimately, the researchers performed a meta-analysis of pre–post results on eight randomized controlled trials, eight open-label extension studies from randomized controlled trials and nine observational controlled studies. These 25 studies included 4,719 patients, 3,160 of whom (67%) completed the studies. The analysis focused on these latter patients.
The investigators found that long-term opioid use resulted in significantly improved function, and physical and mental QOL.
Mark Sullivan, MD, PhD, professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, said that although Dr. Furlan and her collaborators do “careful work,” he had queries about the study, which was presented at the Canadian Pain Society’s 2014 annual meeting (poster 56).
“First, in pre–post studies without a control group, estimates of efficacy are strongly related to who drops out. Since almost all patients who drop out are not doing well on the drug, the mean pre–post differences can grossly overstate efficacy. We are told 67% were completers. How did this 67% compare with those who did drop out?” Dr. Sullivan noted in an email to Pain Medicine News. He also pointed out that the populations in the studies included in the systematic review were not typical.
Dr. Furlan said she and her team discussed at great length these points, and other potential critiques, while they were completing the systematic review.
She said that, for publication, the paper will include an uncertainty analysis that takes into account the worst-case scenario of a high dropout rate and the resulting underestimates of complications and overestimates of opioid effectiveness. Dr. Furlan also conceded that the patients in the systematic review represented a minority of typical chronic pain patients, because they did not have risk factors and were monitored carefully.
“It is true that most of these conditions are not followed in real-life opioid prescribing. [In clinical practice] I see a lot of careless prescribing, which can be characterized as ‘high-risk patients’ and/or ‘high-risk prescriptions.’ When you mix both, it is dangerous,” Dr. Furlan said in an interview with Pain Medicine News. “But when physicians and their teams take the time to carefully screen patients, keep them on as low a dose as possible and monitor them very regularly, our results show that the outcomes can be very satisfactory.”
Tuesday, August 26, 2014
أروى تصارع الموت.. وتطلب العلاج
انتصار الدنان
تاريخ المقال: 27-08-2014 02:25 AM
مع نهاية كل شهر، تطلق عائلة أروى صرخة استغاثة. تتصارع الفتاة مع الموت، أمام عيون عائلتها وزوجها العاجزين مادياً عن تقديم المساعدة لها، لكن ليس من سبيل أمامهم إلا طلب المساعدة علهم يحصلون على بعض منها.
تاريخ المقال: 27-08-2014 02:25 AM
مع نهاية كل شهر، تطلق عائلة أروى صرخة استغاثة. تتصارع الفتاة مع الموت، أمام عيون عائلتها وزوجها العاجزين مادياً عن تقديم المساعدة لها، لكن ليس من سبيل أمامهم إلا طلب المساعدة علهم يحصلون على بعض منها.
ليست أروى الحالة المرضية المستعصية الوحيدة في عين الحلوة. وليست الوحيدة التي تنتظر أمام أبواب المستشفيات أو العيادات، لكي تحصل على العلاج اللازم لها، وتأمين ثمنه. كثيرون لا يستطيعون تأمين ثمن العلاج والدواء، بسبب الحال الاقتصادية المادية، لكنها الحالة التي صرحت عن نفسها، وطالبت المؤسسات الخيرية، والمعنيين، بتأمين العلاج لها، لأنه ضاقت بها الحال أكثر من المتوقع، ولأن مرضها يحتاج إلى علاج دائم، ومكلف جداً مادياً، بحيث تحتاج لعلبتي دواء كل شهر، وبعد الحسم الذي تقوم به «الأونروا» من ثمن الدواء، وتأمين سرير للمريض بالمستشفى، يبقى أن تدفع المبلغ المتبقي من جيبها، والذي يبلغ مليونين ومئتي ألف ليرة.
أروى ميالي، هي شابة فلسطينية، تبلغ من العمر عشرين عاماً، من مخيم عين الحلوة، أم لطفلة تبلغ من العمر ثلاث سنوات، أصيبت منذ عامين بمرض السرطان الذي انتشر بشكل مفاجئ في جسمها، وبعد إصابتها بهذا المرض بدأت رحلتها الطويلة مع المعاناة، فمن مستشفى إلى مستشفى، بحثاً عمن يؤمن لها العلاج بتكلفة أقل، بسبب عدم استطاعة عائلتها وزوجها الذي يعمل في محل لبيع المفروشات أجيراً بمبلغ خمسمئة ألف ليرة.
والد أروى، يوجه «صرخة استغاثة لكل من يهتم بالأمر، ولأصحاب الأيادي البيضاء، للوقوف إلى جانب ابنتي، ومساعدتنا في تأمين العلاج لها». يضيف «لم نتعب من رحلة العلاج الشاقة من مستشفى لآخر، لأن كل ما يعنينا علاج ابنتنا، وبتنا لا نملك سوى رحمة الله. فقد دفعنا كل ما نملك لعلاج ابنتنا، واليوم نقف مكتوفي الأيدي، بسبب عدم وجود الإمكانيات المادية». يتابع «نحن أبناء الشعب الفلسطيني نموت على أبواب المستشفيات، لأننا لا نملك تكاليف علاج أولادنا، وإذا ما تعرض أحدنا للمرض، فإننا نعاني الأمرّين لتأمين العلاج اللازم، ذلك إن استطعنا تأمينه». أما والدتها، فتدعو لها وتقول: «ليس أمامنا إلا انتظار رحمة الله».
زوج أروى، مصطفى أبو غنيم، الذي يكبرها بثلاثة أعوام، ضاقت به السبل في تأمين علاج زوجته. يقول: «لم أعد أستطيع تحمل عبء تكلفة العلاج، لأنني بالأساس لا أملكه. وقد أرسلت نداءات عدة لأصحاب الأيادي البيضاء، كانت تلاقي آذاناً، وتقدم لنا العلاج، لكن علاج زوجتي طويل ودائم، ولا نستطيع أنا وعائلتها تأمينه». ويسأل: «لماذا المريض الفلسطيني يموت على أبواب المستشفيات طلباً للعلاج، لماذا لا تقوم الجهات المعنية بتأمين العلاج، فأنا كل شهر أقف على أبواب المستشفيات، أستجدي ثمن العلاج لزوجتي. وهي اليوم في المستشفى منذ اثني عشر يوماً، بانتظار تأمين بدل مالي للعملية، التي من الضروري جداً إجراؤها لها، حتى تتم عملية إنقاذ حياتها، وإعطاؤها الجرعات اللازمة من العلاج، وهو مستشفى الراعي بغرفة العناية الفائقة، تنتظر الجهات المعنية أن تنقذها من الموت».
Sunday, August 24, 2014
Pain issues in disorders of consciousness.
Brain Inj. 2014;28(9):1202-8.
Abstract
Abstract
Background: The assessment of pain and nociception in non-communicative
patients with disorders of consciousness (DOC) is a real challenge for
clinicians. It is, therefore, important to develop sensitive
standardized tools usable at the bedside.
The first tool which has been developed to assess nociception and pain in patients with disorders of consciousness (DOC) is the Nerve Conduction Studies
NCS. Its revised version represents a rapid, standardized and sensitive scale which can be easily implemented in a clinical setting.
Complementary pain assessments are also under validation in order to offer more options to clinicians.
OBJECTIVES:
This review aims to provide an overview of the current knowledge about pain processing and assessment in patients with DOC.METHODS:
A search was performed on PubMed using MeSH terms including vegetative state, unresponsive wakefulness syndrome, minimally conscious state, consciousness disorders, pain, nociception, neuroimaging and pain assessment.RESULTS:
Neuroimaging studies investigating pain processing in patients with DOC and their implication for clinicians are reviewed. Current works on the development of standardized and sensitive tools for assessing nociception are described.CONCLUSION:
The suggested pain perception capacity highlighted by neuroimaging studies in patients in a Minimally conscious state (MCS) and in some patients in a vegetative state VS/unresponsive wakefulness syndrome UWS supports the idea that these patients need analgesic treatment and monitoring.The first tool which has been developed to assess nociception and pain in patients with disorders of consciousness (DOC) is the Nerve Conduction Studies
NCS. Its revised version represents a rapid, standardized and sensitive scale which can be easily implemented in a clinical setting.
Complementary pain assessments are also under validation in order to offer more options to clinicians.
KEYWORDS:
Minimally conscious state; nociception; pain assessment; unresponsive wakefulness syndrome; vegetative state
CONSCIENCE SHOULD GUIDE DOCTORS AT
END OF LIFE
aura Eggertson, Ottawa, Ont.
END OF LIFE
aura Eggertson, Ottawa, Ont.
August 19, 2014
All doctors have the
right to follow their conscience when deciding whether to assist dying
patients physically or to provide
them with the means to end their lives
— within the bounds of legislation, delegates to the Canadian Medical
Association's
annual meeting have voted.
As Canada considers changingits laws concerning assisted death, Canada's doctors considered their stance on the second
day of the Canadian Medical Association's (CMA) 147th annual meeting in Ottawa. In the end, they voted 91% in favour of allowing individual physicians to follow their conscience
in deciding whether or not to provide assistance.
The association's
current 2007 policy states that physicians should not provide such
assistance, but as laws change, most
recently Bill 52 in Quebec, CMA decided
to revisit its policy. CMA President Dr. Louis Hugo Francescutti says
general council's
wishes will be discussed by the CMA Board
of Directors later this week or in October. "I can't predict what is
going to come
out of it, but I am hopeful."
CMA's French-language spokesperson
Dr. Pierre Harvey explained that it's not up to physicians to take a
stance for or against
the issue; that's the responsibility of
society. However, physicians can say what they want to do. "The motion
was inspired
by respect for our diversity," he said.
The motion represents
major progress over last year, when delegates at the annual meeting
couldn't even agree on terminology.
In the intervening months, CMA hosted a
series of town hall meetings across Canada on the topic. "The town
halls galvanized
our view around this," said Francescutti.
The terminology was
changed to physician-assisted death at this year's meeting and doctors
were encouraged to voice their
views during a nearly three-hour session.
The complex ethical issue involves the physician's ability to meet
terminal patients'
requests to end their suffering or
expected loss of control; the effectiveness of and access to palliative
care; and their
own legal liabilities and
responsibilities.
Canadians need better, more equitable access to palliative care, doctors agreed. But even a national strategy and better
access to pain relief will not negate the need for medical aid in dying, many doctors concluded.
For some patients, doctors who provide morphine and sedatives are not only giving pain relief, "we are actively facilitating
their death," said Dr. Paul Parks, an emergency physician from Medicine Hat, Alberta.
The stories doctors related on August 19 were as personal as they were professional. They acknowledged the often agonizing
dilemmas patients, their families and their doctors face.
Dr. Sarah Bates, a
Calgary family doctor, addressed delegates as a caregiver and potential
future patient, she said. "My
Mom developed familial Alzheimer's in her
early 50s. My sister has just been diagnosed — she is 43. So these
issues weigh
very heavily on my mind," Bates told about
250 delegates and close to 400 observers.
"There are conditions,
we all know, where no level of oxygen, morphine or supportive
counseling is going to provide relief
of suffering. Just because we have a
respiratory drive, a swallowing reflex and a beating heart doesn't mean
we have a life.
''
The CMA is discussing
the issue of end-of-life care in the context of an upcoming Supreme
Court of Canada decision that
is expected to rule in October on the
legality of physician-assisted death. The CMA has been granted status to
intervene
as a "friend of the court" in the case,
and will be presenting the complexities of these issues from doctors'
perspectives,
Dr. Jeff Blackmer, the association's
executive director of ethics, professionalism and international affairs
told delegates.
Quebec has passed
legislation permitting medical aid in dying, under particular
circumstances and after consultation with
more than one doctor. That law is
expected to take effect in late 2015 unless it is the subject of a
federal constitutional
challenge.
The bill may well make
Dr. Angela Genge, who heads the Montreal Neurological Institute's
amyotrophic lateral sclerosis
(ALS) clinic, the first doctor in Quebec
asked to comply with the law. That's because her patients with ALS and
other terminal
neurodegenerative diseases regularly ask
her to help them end their lives.
"My ALS patients are
very bright," Genge told delegates. "They can be any one of you in the
room." Her patients fear loss
of control, suffering, and being a burden
on their families. Most of all, they want permission to discuss how and
when they
want to die.
Every patient has the right to have that discussion, Genge said, and Quebec's law provides clarity around that right and
ensures it can take place, even if it doesn't alter how a doctor responds to these requests.
"The minute I do not
allow my patient to discuss their desire to be in control of their
death, I actually break the patient-physician
relationship," she added. "My patients
are as intelligent as you and I are and they have the right to have
that discussion."
All of her patients have, however,
ultimately "changed the goalposts" they initially set for themselves
about what point
in their illness they would choose to end
their life. That's the reason Genge hopes the regulations that
accompany the Quebec
legislation will not fix a time period in
which physicians have to respond to a patient's request for help ending
their life.
In addition to passing a
motion supporting physicians' right to act according to their
conscience, the delegates also instructed
the CMA to investigate and communicate
Inuit, Metis and First Nations' perspectives on euthanasia,
physician-assisted death
and end-of-life care. Physicians must be
sensitive to the experience of many Aboriginal communities already
coping with high
levels of suicide, and in particular teen
suicide, Dr. David Pontin, the president of the Northwest Territories
Medical
Association, pointed out.
It is also critical
that the CMA develop a strategy to make sure there are enough doctors
trained to deliver palliative
care across Canada. Currently, Canada
needs at least another 300 palliative care specialists, Dr. Doris
Barwich of the Canadian
Society of Palliative Care Physicians told
delegates. In addition, 75% of doctors have identified their need for
further
palliative care help and education, she
added.
Other family
physicians, however, described their current cradle-to-grave practices
involving palliative care and suggested
that with greater education and support,
more doctors could provide these services that Canadians have repeated
stated they
want and need.
"All doctors want is a
little bit of help, mostly around prescribing narcotics," said
Dr. Suzanne Strasberg, a family physician
in Toronto. "What we need is: we need
education. I think we should be ready to do this work."
The CMA will support
the development of an advanced care planning, palliative and
end-of-life care strategy in all provinces
and territories, delegates agreed, while
leaving it to the broader Canadian public and legislators to change the
laws around
medical aid in dying.
DOI:10.1503/cmaj.109-4880
The 269 delegates voted
to "support the right of all physicians, within the bounds of existing
legislation, to follow their
conscience when deciding whether to
provide medical aid in dying."
Barbara Sibbald, CMAJ
August 22, 2014
Medical marijuana and senior's care were extensively
debated at the Canadian Medical Association (CMA) 147th annual meeting in Ottawa Aug. 17–20, but physician-assisted death was the main action-item.
The 269 delegates voted
to "support the right of all physicians, within the bounds of existing
legislation, to follow their
conscience when deciding whether to
provide medical aid in dying." That resolution, which was approved by
91% of delegates,
will now be considered by CMA's Board of
Directors.
CMA's 2007 policy states
that doctors should not participate in euthanasia or assisted suicide.
The new position prepares
physicians for the possibility that laws
may be changing in light of a recent Quebec bill and an upcoming case
at the Supreme
Court of Canada.
In a related move, delegates asked CMA to develop a strategy to ensure there are enough doctors trained in palliative care.
The annual meeting began
with the release of a survey and a call for a national seniors' health
care strategy. The survey
of 1000 Canadians (aged 45 and older)
found that 95% saw the need for a pan-Canadian Seniors' care strategy
— a percentage
outgoing CMA president Louis Hugo
Francescutti called "astonishing." "Federal politicians should worry
about this if they
want to stay federal politicians," he
told CMAJ.
CMA's new president, Dr. Chris Simpson
from Kingston, Ont., said the failure to address seniors' needs
"impacts every single
component of the health care system." For
example, "warehousing of seniors in hospital beds" wastes about
$2.3 billion annually.
In his inaugural
address, Simpson also slammed the federal government for its inaction on
medicare. He cited a recent report
from the Commonwealth Fund indicating that
Canada's health system ranks second last on virtually every measure of
quality
and access. Top-ranked countries all have
"strong leadership" from a committed federal government. He urged the
federal
government to begin with a comprehensive
seniors care strategy.
Federal Health Minister Rona Ambrose said a national strategy is "valid, but only possible if the provinces and territories
want it." So far, "there's been no call for one, except from certain groups."
Ambrose also spoke
about the need for government and physicians to work on practical
solutions to Canada's prescription
drug abuse problem. A "frightening" number
of Canadians — some 410 000 — abuse prescription drugs, she said.
"Doctors are
prescribing too much."
She also responded to
concerns about Canada's new medical marijuana law, which puts
physicians in a "precarious situation."
"The majority of doctors don't want to
prescribe and I would encourage them not to do it if they don't want
to," she said.
At the same time, she insisted that
doctors are the best gatekeepers to marijuana.
Francescutti said the new law, which came into effect Apr. 1, 2014, "strains the physician-patient relationship."
"It's just plain bad medicine to prescribe a product when we don't know how it works; we don't know when it works, who it
works for, how it interacts or how much to prescribe."
The CMA's long-standing
position is that there is insufficient evidence supporting marijuana's
use as a therapeutic agent.
Delegates approved a motion calling for
the CMA to speak out against smoking any plant material, clearly aimed
at marijuana.
Respirologist Dr. Deborah Hellyer noted
that smoking one joint is the equivalent of up to 10 cigarettes.
A second motion called
for licensing bodies to develop comprehensive regulatory standards to
guide physicians in prescribing
marijuana. Currently the information
available and policies vary. "We need clear and consistent standards,"
said Francescutti.
New president elect
Delegates confirmed the
election of CMA President Elect Dr. Cindy Forbes, a family physician
from Waverley, Nova Scotia.
Her term as president begins August 2015.
Forbes has practiced as a family physician for 28 years in Nova Scotia
and British
Columbia.
"My goal as president is
to identify and promote innovative solutions and positive change for
health care," she stated in
a media release. She identified seniors
care and the health care transformation initiative as two areas of
engagement.
Forbes is the former president of Doctors Nova Scotia (1996/97) and has chaired CMA's Council on Health Care and Promotion.
During the meeting, CMA
also received the Canadian Forces Medallion for Distinguished Service.
It recognizes CMA's long-time
support for the Canadian Forces, from the
creation of the first permanent military medical service in 1899 to
recruitment
of physicians during the recent mission
in Afghanistan.
And last but not least, for the first time in 15 years, there will be no increase in CMA fees; they stand at $495 annually.
Visit cmaj.ca for extensive news coverage of the annual meeting.
Friday, August 22, 2014
Thursday, August 21, 2014
German spirituality – spirituality in Germany
Posted on August 20, 2014 by pallcare
Lukas Radbruch, President of the German Association for Palliative Care, and Chair of Palliative Medicine at the University of Bonn, Germany.
Rev Joep van de Geer, co-chair of the EAPC Task Force on
Spirituality, recently contributed a post about the translation of the
Dutch Guideline on Spiritual Care into German following a German course
on spirituality in Mainz. The EAPC task force has translated the
guideline as an example of the myriad of valuable tools and documents
that are available in various countries, albeit only in the native
language.
Without doubt, this translation will be very useful for palliative
care or spiritual care professionals in Germany. However, reading the
guideline I’d like to point out that there is a vibrant development in
spiritual care in Germany, and a number of tools on spiritual care are
already available. Here is some information on other German resources,
with a rather random selection by me.
- There is a Task Force on Spiritual Care within the German Association for Palliative Care, and the task force has published a paper on “What is spiritual care?” that is available online. This position paper from 2007 describes what spiritual care is, what are the tasks in clinical palliative care, in education and research, and in media work.
- Traugott Roser has an academic chair for spiritual care in Munich, and he cooperates closely with the chair for social care (Maria Wasner) and the chair for palliative medicine (Claudia Bausewein) in the same city. There is a lot of education and research going on in his department. Traugott Roser is also the editor of an online journal on spiritual care. The latest issue in 2014 includes original papers on knowledge and opportunities for volunteers in psychosocial crisis intervention, on behaviourial therapy and spirituality as well as on the competencies of emergency spiritual care givers.
- Traugott Roser has also written an excellent German textbook entitled ‘Spiritual Care’ and, together with Thomas Hagen, Hermann Reigber and Bernadette Fittkau-Tönnesmann, a curriculum on palliative care for spiritual care givers.
- Another excellent book is by Monika Müller, with many stories and reflections on how to accompany dying or grieving people as a spiritual pathway (‘Dem Sterben Leben geben: Die Begleitung sterbender und trauernder Menschen als spiritueller Weg’). I often use this for training courses of physicians.
There is a lot more in German language out there and I am sure that I
have missed out on some important resources. Spiritual care really
seems to be a most interesting topic in palliative care in Germany, as
well as elsewhere.
I agree completely with Joep van de Geer that it is worthwhile to
compare tools and resources between countries, languages and cultures. I
hope the EAPC task force will continue with the translation of other
material to facilitate exchange and comparison. There is so much to be
gained from this exchange!
Links and resources
- ‘The Dutch Guideline on Spiritual Care’ (German and English translations).
- You can read more posts about spiritual care in palliative care on the EAPC blog, including Joep van de Geer’s post published on 18 August.
- Selected EAPC documents are now translated into 23 languages – please visit our new ‘EAPC documents in other languages’ on the EAPC website.
Subscribe to:
Posts (Atom)